Arbutus Biopharma
Arbutus Biopharma moves to terminate development of chronic hepatitis B therapy after trial failure
October 4, 2019Medical Communications, Research and Development Arbutus Biopharma, hepatitis B, pharma
Arbutus Biopharma has announced its decision to terminate the development of its oral capsid inhibitor, known as AB-506, in the …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
